MARKET

MRSN

MRSN

Mersana Therapeutics Inc
NASDAQ
29.08
0.00
0.00%
Suspension 18:40 01/05 EST
OPEN
--
PREV CLOSE
29.08
HIGH
--
LOW
--
VOLUME
0
TURNOVER
--
52 WEEK HIGH
36.25
52 WEEK LOW
5.21
MARKET CAP
145.36M
P/E (TTM)
-2.0646
1D
5D
1M
3M
1Y
5Y
1D
Mersana Therapeutics Completes Merger and Delists from Nasdaq
TipRanks · 7h ago
Mersana Therapeutics Shareholders to Receive $25 Per Share in Acquisition by Day One Biopharmaceuticals
Reuters · 8h ago
NASDAQ TRADE HALT <MRSN.O> TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Reuters · 21h ago
Weekly Report: what happened at MRSN last week (1229-0102)?
Weekly Report · 1d ago
Weekly Report: what happened at MRSN last week (1222-1226)?
Weekly Report · 12/29/2025 10:14
Weekly Report: what happened at MRSN last week (1215-1219)?
Weekly Report · 12/22/2025 10:14
Weekly Report: what happened at MRSN last week (1208-1212)?
Weekly Report · 12/15/2025 10:21
Serina Therapeutics Appoints Dr. Joshua Thomas as Vice President and Head of Chemistry
Reuters · 12/11/2025 21:15
More
About MRSN
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development of antibody-drug conjugates (ADCs), which offer a clinically meaningful benefit for cancer patients with significant unmet needs. It has developed two proprietary and differentiated ADC platforms: Dolasynthen and Immunosynthen. Dolasynthen is a cytotoxic ADC platform that is designed to generate site-specific, homogeneous ADCs. Immunosynthen is its proprietary stimulator of interferon genes (STING)-agonist platform that is designed to generate systemically administered ADCs that locally activate STING signaling in both antigen-expressing tumor cells and in tumor-resident immune cells. The Company's pipeline includes Emi-Le (emiltatug ledadotin; XMT-1660), a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2).

Webull offers Mersana Therapeutics Inc stock information, including NASDAQ: MRSN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MRSN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MRSN stock methods without spending real money on the virtual paper trading platform.